Notably, tasquinimod induced apoptosis in JAK2V617F cells, both in vitro and in vivo, corroborating similar findings in multiple myeloma and acute myeloid leukemia where tasquinimod, especially in combination with venetoclax, led to reduced MYC targets, cell cycle regulators, and mTORC1 signaling.17 This evidence concerns the gene MYC and plasma cell myeloma.